Literature DB >> 29229603

LNMICC Promotes Nodal Metastasis of Cervical Cancer by Reprogramming Fatty Acid Metabolism.

Chunliang Shang1, Wei Wang1, Yuandong Liao1, Yili Chen1, Tianyu Liu1, Qiqiao Du1, Jiaming Huang1, Yanchun Liang1, Junxiu Liu1, Yunhe Zhao1, Luyan Guo1, Zheng Hu2, Shuzhong Yao2.   

Abstract

Cancer spread to lymph nodes predicts poor survival but underlying mechanisms remain little understood. In this study, we show that overexpression of the long noncoding RNA LNMICC associates with lymph node metastasis of primary cervical cancer, where it serves as an independent high-risk factor in patient survival. Functional investigations demonstrated that LNMICC promoted lymph node metastasis by reprogramming fatty acid metabolism, by recruiting the nuclear factor NPM1 to the promoter of the fatty acid binding protein FABP5. We also found that the prometastatic effects of LNMICC were directly targeted and suppressed by miR-190. Our results establish a new mechanism of lymph node metastasis and highlight LNMICC as a candidate prognostic biomarker and therapeutic target in cervical cancer.Significance: These results establish the role of a novel long noncoding RNA in lymph node metastasis, with implications as a candidate prognostic biomarker and therapeutic target in cervical cancer. Cancer Res; 78(4); 877-90. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29229603     DOI: 10.1158/0008-5472.CAN-17-2356

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  The Immunological Contribution of a Novel Metabolism-Related Signature to the Prognosis and Anti-Tumor Immunity in Cervical Cancer.

Authors:  Sihui Yu; Xi Li; Mingjun Ma; Rui Yang; Jiawen Zhang; Sufang Wu
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

Review 2.  Long non-coding RNAs involved in cancer metabolic reprogramming.

Authors:  Hui Liu; Junyun Luo; Siyu Luan; Chongsheng He; Zhaoyong Li
Journal:  Cell Mol Life Sci       Date:  2018-10-19       Impact factor: 9.261

Review 3.  The metabolism of cancer cells during metastasis.

Authors:  Gabriele Bergers; Sarah-Maria Fendt
Journal:  Nat Rev Cancer       Date:  2021-01-18       Impact factor: 60.716

4.  Lipid metabolism regulator human hydroxysteroid dehydrogenase-like 2 (HSDL2) modulates cervical cancer cell proliferation and metastasis.

Authors:  Yang Yang; Anna Han; Xinyue Wang; Xianglin Yin; Minghua Cui; Zhenhua Lin
Journal:  J Cell Mol Med       Date:  2021-03-18       Impact factor: 5.310

5.  Long noncoding RNA LINC00460 promotes the progression of cervical cancer via regulation of the miR-361-3p/Gli1 axis.

Authors:  Fan Li; Weipei Zhu; Zhijie Wang
Journal:  Hum Cell       Date:  2020-10-16       Impact factor: 4.374

6.  FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism.

Authors:  Chunyu Zhang; Yuandong Liao; Pan Liu; Qiqiao Du; Yanchun Liang; Shiyin Ooi; Shuhang Qin; Shanyang He; Shuzhong Yao; Wei Wang
Journal:  Theranostics       Date:  2020-05-17       Impact factor: 11.556

Review 7.  Emerging roles of long non-coding RNAs in tumor metabolism.

Authors:  Hui Sun; Zhaohui Huang; Weiqi Sheng; Mi-Die Xu
Journal:  J Hematol Oncol       Date:  2018-08-22       Impact factor: 17.388

8.  Identification of an Metabolic Related Risk Signature Predicts Prognosis in Cervical Cancer and Correlates With Immune Infiltration.

Authors:  Chunliang Shang; Jiaming Huang; Hongyan Guo
Journal:  Front Cell Dev Biol       Date:  2021-06-24

Review 9.  Fatty acid oxidation: driver of lymph node metastasis.

Authors:  Mao Li; Hong-Chun Xian; Ya-Jie Tang; Xin-Hua Liang; Ya-Ling Tang
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722

10.  Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT.

Authors:  Qing Li; Zhi-Wei Zhou; Wei Duan; Cheng-Yuan Qian; Shu-Nan Wang; Meng-Sheng Deng; Dan Zi; Jian-Min Wang; Cheng-Yi Mao; Guanbin Song; Dong Wang; Kenneth D Westover; Cheng-Xiong Xu
Journal:  J Exp Clin Cancer Res       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.